KM

KIRBY MILLER

BRISTOL-MYERS SQUIBB COMPANY · WASHINGTON, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
3
3 agencies contacted
Activity
filings by quarter
Works on

Background

Government experience
LA - U.S.Senateor RWicker
2020-2022); U.S.House Dep. CoS Rep. Trent Kelly (2019-2020); LD,LA,LC U.S.House Rep Rod Blum (2015-2019); U.S.House Staff Asst Rep. Stephen Fincher(2014-2015
Disclosed on LD-2 filings
Career
WASHINGTON, DC
2024 - present

Specific issues

Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act Biosimilars reimbursement issues
Health Issues · 2024 Q4
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act H.R.9747, Continuing Appropriations and Extensions Act
Pharmacy · 2024 Q4
Intellectual Property Reform concerning bio-pharmaceutical industry Discussions regarding the Patent Eligibility Restoration Act
Copyright/Patent/Trademark · 2024 Q4
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
Medicare/Medicaid · 2024 Q4
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Health Issues · 2024 Q3
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
Pharmacy · 2024 Q3

Clients

$██,███ / qtrUnlock

Filing history

2024 Q4
BRISTOL-MYERS SQUIBB COMPANY
Q4lda.gov →
2024 Q3
BRISTOL-MYERS SQUIBB COMPANY
Q3lda.gov →
2024 Q2
BRISTOL-MYERS SQUIBB COMPANY
Q2lda.gov →
Showing recent filings · full history on lda.gov